| Original language | English |
|---|---|
| Pages (from-to) | 2298-2300 |
| Number of pages | 3 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 14 |
| Issue number | 20 |
| DOIs | |
| State | Published - 25 Oct 2021 |
Keywords
- TAVR
- coronary obstruction
- leaflet height
- redo TAVR
- valve degeneration
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JACC: Cardiovascular Interventions, Vol. 14, No. 20, 25.10.2021, p. 2298-2300.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Leaflet and Neoskirt Height in Transcatheter Heart Valves
T2 - Implications for Repeat Procedures and Coronary Access
AU - Akodad, Mariama
AU - Sellers, Stephanie
AU - Gulsin, Gaurav S.
AU - Tzimas, Georgios
AU - Landes, Uri
AU - Chatfield, Andrew G.
AU - Chuang, Anthony
AU - Meier, David
AU - Leipsic, Jonathon
AU - Blanke, Philippe
AU - Ye, Jian
AU - Cheung, Anson
AU - Wood, David A.
AU - Khan, Jaffar M.
AU - Webb, John G.
AU - Sathananthan, Janarthanan
N1 - Funding Information: The authors thank St. Paul's Foundation and the Providence Health Care Research Institute Early Career Research Initiative. Funding Information: Dr Sellers is supported by fellowships from the Canadian Institutes of Health Research and the Michael Smith Foundation for Health Research. Dr Gulsin is supported by a British Heart Foundation Travel Fellowship (FS/TF/21/33008). Dr Tzimas is supported by the Fondation Vaudoise de Cardiologie. Dr Chatfield is funded by the New Zealand Heart Foundation and a John Ormiston Scholarship. Dr Chuang is funded by a Royal Australasian College of Physicians Vincent Fairfax Research Entry Scholarship. Dr Meier is supported by the Swiss National Science Foundation (grant P2LAP3_199561). Dr Akodad has received research funding from Medtronic, Biotronik, MUSE Explore, and Federation Française de Cardiologie. Dr Leipsic has served as the Canadian Research Chair in Advanced CardioPulmonary Imaging; served as a consultant for MVRX, HeartFlow, and Circle Cardiovascular Imaging; and provided computed tomography core lab services for Edwards Lifesciences, Medtronic, Neovasc, Boston Scientific, and Tendyne Holdings, for which no direct compensation is received. Dr Blanke has served as a consultant to Edwards Lifesciences; and provided computed tomography core lab services for Edwards Lifesciences, Medtronic, Neovasc, Guided Delivery Systems, and Abbott, for which no direct compensation has been received. Dr Ye has served as a consultant to Edwards Lifesciences and JC Medical. Dr Wood has served as a consultant to and received research funding from Edwards Lifesciences and Abbott. Dr Webb has served as a consultant for Edwards Lifesciences and Abbott. Dr Sathananthan has received speaker fees from Edwards Lifesciences; and served as a consultant for Edwards Lifesciences, Boston Scientific, NVT Medical, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2021/10/25
Y1 - 2021/10/25
KW - TAVR
KW - coronary obstruction
KW - leaflet height
KW - redo TAVR
KW - valve degeneration
UR - http://www.scopus.com/inward/record.url?scp=85116892334&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2021.07.034
DO - 10.1016/j.jcin.2021.07.034
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34600879
AN - SCOPUS:85116892334
SN - 1936-8798
VL - 14
SP - 2298
EP - 2300
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 20
ER -